Vaccine Therapy in Treating Patients With Melanoma

Status Completed

Clinical Trial Summary

Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells. Combining more than one vaccine may kill more tumor cells.

Clinical Trial Description

OBJECTIVES:

I. Determine the toxic effects associated with ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 in patients with surgically incurable melanoma.

II. Characterize the inflammatory and lymphokine response to this regimen in these patients.

III. Examine the extent of nodule regression, humoral immune response, and cytolytic T cell activity with this regimen in these patients.

OUTLINE: This is a dose escalation study of ALVAC-hB7.1

Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.

Patients are followed at 1, 2, 4, 8, 11, 15, 22, and 43 days after the first vaccination. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003556
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 1
Start date	January 1999

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04062032` - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma	Phase 2
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Active, not recruiting	`NCT03291002` - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC	Phase 1
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Completed	`NCT00962845` - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery	Early Phase 1
Completed	`NCT00324623` - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma	Phase 1
Completed	`NCT00096382` - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00104845` - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 1
Completed	`NCT00089193` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 2
Completed	`NCT00072085` - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00072124` - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma	Phase 3
Active, not recruiting	`NCT00039234` - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver	Phase 3
Completed	`NCT00042783` - Vaccine Therapy in Treating Patients With Stage IV Melanoma	Phase 2
Completed	`NCT00049010` - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma	N/A
Completed	`NCT00006022` - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer	Phase 1
Completed	`NCT00006385` - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00005610` - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung	Phase 2
Completed	`NCT00020358` - Vaccine Therapy in Treating Patients With Melanoma	Phase 2
Recruiting	`NCT03767348` - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	Phase 2
Withdrawn	`NCT00006126` - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery	Phase 1